Text Size

Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)

This study is currently recruiting participants.
Verified April 2013 by Sequenom, Inc.
Sponsor:
Information provided by (Responsible Party):
Sequenom, Inc.
ClinicalTrials.gov Identifier:
NCT01682382
First received: September 6, 2012
Last updated: April 10, 2013
Last verified: April 2013
History of Changes
  Purpose

Subjects with wet AMD, dry AMD, and age-matched controls will undergo routine occular measurements, will provide a blood and cheek cell sample, and will have macular pigment optical density (MPOD) measured to determine if there is an association between genetics, MPOD and the risk of progression to wet AMD.


Condition
Age-related Macular Degeneration
Choroidal Neovascular Age-related Macular Degeneration

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Collection of Whole Blood Specimens and Buccal Swabs From Subjects Diagnosed With CNV AMD, Dry AMD, and Age-Matched Controls to Assess the Association of Genetic Variants in Complement Factor H With Risk of Progression to CNV.

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Sequenom, Inc.:

Primary Outcome Measures:
  • Association between a genetic variant in the CFH gene and risk of progression to CNV [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    DNA extracted from blood and buccal cells collected from subjects with either CNV, dry AMD, and age-matched controls will be analyzed to investigate a genetic variant in the CFH gene and its association with risk of progression to CNV


Secondary Outcome Measures:
  • Genetic correlation between MPOD and risk of progression to CNV [ Time Frame: baseline ] [ Designated as safety issue: No ]
    DNA extracted from blood and buccal cells collected from subjects with either CNV, dry AMD, and age-matched controls will be analyzed to investigate the correlation between genetics, MPOD, and risk of progression to CNV


Biospecimen Retention:   Samples With DNA

DNA extracted from whole blood and buccal cells will be analyzed. Remnant samples will be stored for future research in AMD.


Estimated Enrollment: 150
Study Start Date: August 2012
Estimated Study Completion Date: October 2013
Estimated Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
choroidal neovascular (CNV) AMD subjects
Subjects diagnosed with CNV (AREDS Grade 4b)
dry AMD subjects
Subjects diagnosed with dry AMD (AREDS Grade 3)
age-matched controls
Subjects without AMD (AREDS Grade 1)

  Eligibility

Ages Eligible for Study:   60 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Non-Hispanic Caucasian subjects 60 years of age and older diagnosed with either CNV or dry AMD and a cohort of age-matched controls

Criteria

Inclusion Criteria:

  • subject is diagnosed with either CNV, dry AMD or is an age-matched control
  • self reported as non-Hispanic Caucasian
  • 60 years of age or older
  • provides signed and dated informed consent
  • agrees to provide 10 mL of whole blood and two buccal swabs

Exclusion Criteria:

  • previous donation under this protocol
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01682382

Locations
United States, California
Morris Eye Group Recruiting
Encinitas, California, United States, 92024
Contact: Jessica McAvinue     760-631-3500 ext 149     jmcavinue@morriseyegroup.com    
Principal Investigator: Jeffrey B Morris, MD, MPH            
Sponsors and Collaborators
Sequenom, Inc.
  More Information

No publications provided

Responsible Party: Sequenom, Inc.
ClinicalTrials.gov Identifier: NCT01682382     History of Changes
Other Study ID Numbers: SQNM-AMD-103
Study First Received: September 6, 2012
Last Updated: April 10, 2013
Health Authority: United States: IRB approved

Keywords provided by Sequenom, Inc.:
age-related macular degeneration
choroidal neovascular age-related macular degeneration
genetics
macular pigment optical density (MPOD)

Additional relevant MeSH terms:
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Complement Factor H
 Complement Inactivating Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 23, 2013